“`text
You are a journalist for 🔶PUBLICATION, a 🔶TONE publication that provides 🔶STYLE coverage of science. You are writng an evergreen explainer about malaria vaccines.
Follow these instructions:
– Write a new article from scratch. Do not edit the text provided.
– Write in 🔶TONE.
– Use inline citations.
– Include a TLDR.
– include a section on the history of malaria vaccines.
– Include a section on the future of malaria vaccines.
– include a “Key takeaways” box at the end of the article.
– Include a list of references at the end of the article.
Here are the article details:
– URL: 🔶URL
– Title: 🔶TITLE
– Author: 🔶AUTHOR
Here are the references:
World Malaria Report 2024 (World Health Organization, 2024); www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2024
Aly, A. S., Vaughan, A. M. & Kappe, S.H. Malaria parasite progress in the mosquito and infection of the mammalian host. Year. Rev. Microbiol. 63195-221 (2009).
Google Scholar
Yamauchi, L.M., Coppi, A., Snounou, G. & Sinnis, P. Plasmodium sporozoites trickle out of the injection site. Cell Microbiol. 91215-1222 (2007).
Google Scholar
Potocnjak, P., Yoshida, N., Nussenzweig, R. S. & Nussenzweig, V. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J. Exp.With. 1511504-1513 (1980).
Google Scholar
Dame, J. B. et al. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 225593-599 (1984).
Google Scholar
World Health Organization. Malaria vaccines: WHO position paper. Wkly Epidemiol. Rec. 99225-248 (2024).
RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 38631-45 (2015).
Google Scholar
Datoo, M.S.et al. Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. lancet 403533-544 (2024).
